Youth Working with Girls and Women in Community Settings: A Feminist Perspective
In: The British journal of social work, Volume 44, Issue 1, p. 185-186
ISSN: 1468-263X
5 results
Sort by:
In: The British journal of social work, Volume 44, Issue 1, p. 185-186
ISSN: 1468-263X
In: Political psychology: journal of the International Society of Political Psychology, Volume 1, Issue 2, p. 87
ISSN: 1467-9221
In: Journal of the International AIDS Society, Volume 15, Issue S4, p. 1-1
ISSN: 1758-2652
We present baseline data (follow up due w24–48) from MSM Neurocog ‐ prospective cohort study describing neurocognitive (NC) function in men who have sex with men (MSM) 18–50y.ObjectivesDescribe prevalence of positive screen for NC impairment (NCI) using Brief Neurocognitive Screen (BNCS); follow NC function over time.Data collectedDemographics, medical history, current/nadir CD4, current/peak viral load, antiretroviral (ART) use, recreational drug/tobacco/alcohol use. Subjects screen for depression (PHQ9), anxiety (GAD7), subjective memory problems (Everyday Memory Questionnaire [EMQ]). PHQ9, GAD7, EMQ, IHDS have fixed numerical cut‐offs. BNCS interpreted by calculating composite z score for each subject based on distance from mean in three component tests. Comparing to population norms may overcall NCI. We used participants to construct HIV+ normal ranges after exclusion of anxiety/depression, comparing individuals to this range. 235 screened (205 HIV+, 30 HIV−). In HIV+group 59 (28.8%) excluded as GAD7>10, PHQ9>15 or both (2 no data). 144 HIV+ analysed. 124 (86.1%) had normal z score (within 1 SD of mean). 20 (13.9%) had abnormal z: 7 (35%) asymptomatic, 13 (65%) symptomatic (analysed together). Not enough cognitive domains assessed by BNCS to formally diagnose HIV‐related NCI. BNCS abnormals less likely to be educated at university level/beyond (40% vs. 62.1%, p=0.02) or in skilled work (45% vs. 81.5%, p<0.0001). Current/ex‐recreational drug use similar (~80%); no significant association to score. All patients with abnormal z receiving ART; individual agents not associated with abnormality. IHDS correlated with abnormal BNCS (60% abnormal z had abnormal IHDS vs. 15.3% of normal, p<0.0001). No CD4 association with abnormal z (median nadir 244 in both, p=0.38). Of note, group median age was statistically different but actual difference small (normal 41y vs. abnormal 44y p<0.0001; HIV− 33y). BNCS outcome is age‐related but stratification of results would make abnormal numbers too low for interpretation. In any case, no NCI seen following referral. No‐one referred for formal psychometric testing after screening shown to have NCI. We show high anxiety, depression and current/previous recreational drug use in HIV+MSM 18–50y. Subjective concerns do not translate into confirmed NCI. Patient pathways should include screening for anxiety/depression and substance use, but in this young MSM group concerns regarding memory/functional impairment seem unfounded.
We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARCARC, Australia; BMWF and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST, and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR, and VSC CR, Czech Republic; DNRF, DNSRC, and Lundbeck Foundation, Denmark; EPLANET, ERC, and NSRF, European Union; IN2P3-CNRS, CEA-DSM/IRFU, France; GNSF, Georgia; BMBF, DFG, HGF, MPG, and AvH Foundation, Germany; GSRT and NSRF, Greece; ISF, MINERVA, GIF, DIP, and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; FOM and NWO, Netherlands; BRF and RCN, Norway; MNiSW, Poland; GRICES and FCT, Portugal; MERYS (MECTS), Romania; MES of Russia and ROSATOM, Russian Federation; JINR; MSTD, Serbia; MSSR, Slovakia; ARRS and MIZŠ, Slovenia; DST/NRF, South Africa; MICINN, Spain; SRC and Wallenberg Foundation, Sweden; SER, SNSF and Cantons of Bern and Geneva, Switzerland; NSC, Taiwan; TAEK, Turkey; STFC, the Royal Society and Leverhulme Trust, United Kingdom; DOE and NSF, United States of America. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular, from CERN and the ATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK), and BNL (USA) and in the Tier-2 facilities worldwide.
BASE
We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWF and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMT CR, MPO CR and VSC CR, Czech Republic; DNRF, DNSRC and Lundbeck Foundation, Denmark; EPLANET, ERC and NSRF, European Union; IN2P3-CNRS, CEA-DSM/IRFU, France; GNSF, Georgia; BMBF, DFG, HGF, MPG and AvH Foundation, Germany; GSRT and NSRF, Greece; ISF, MINERVA, GIF, DIP and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; FOM and NWO, Netherlands; BRF and RCN, Norway; MNiSW, Poland; GRICES and FCT, Portugal; MERYS (MECTS), Romania; MES of Russia and ROSATOM, Russian Federation; JINR; MSTD, Serbia; MSSR, Slovakia; ARRS and MIZŠ, Slovenia; DST/NRF, South Africa; MICINN, Spain; SRC and Wallenberg Foundation, Sweden; SER, SNSF and Cantons of Bern and Geneva, Switzerland; NSC, Taiwan; TAEK, Turkey; STFC, the Royal Society and Leverhulme Trust, United Kingdom; DOE and NSF, United States of America. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN and the ATLAS Tier-1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA) and in the Tier-2 facilities worldwide.
BASE